PA
LXEO icon

Perceptive Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Perceptive Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-139,835
Closed -$1.39M – 118
2025
Q4 		$1.39M Hold
139,835
– – 0.02% 106
2025
Q3 		$929K Hold
139,835
– – 0.03% 86
2025
Q2 		$562K Hold
139,835
– – 0.02% 80
2025
Q1 		$485K Hold
139,835
– – 0.02% 81
2024
Q4 		$920K Hold
139,835
– – 0.03% 90
2024
Q3 		$1.26M Buy
+139,835
New +$1.67M 0.03% 98

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors's LXEO Position: Q1 2026 in Review

Perceptive Advisors sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 139,835 shares — an estimated $1.39M sold.

Perceptive Advisors first reported a position in LXEO in Q3 2024 and held it in 6 quarters. The position peaked at $1.39M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Perceptive Advisors reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Perceptive Advisors sold 139,835 Lexeo Therapeutics shares in Q1 2026, an estimated $1.39M.
  • Perceptive Advisors first reported a position in Lexeo Therapeutics in Q3 2024 and held it in 6 quarters.
  • Perceptive Advisors's Lexeo Therapeutics position peaked at $1.39M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.